Long-acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations.

Cabenuva (cabotegravir long acting/rilpivirine long acting) - J&J, GSK, ViiV Healthcare, Pfizer, Shionogi

http://www.ncbi.nlm.nih.gov/pubmed/42722419

Andrea Giacomelli; Andrea Gori; Anna Lisa Ridolfo; Carlo Federico Perno; Cinzia Fasola; Cristina Gervasoni; Dario Cattaneo; Davide Dalu; Giacomo Pozza; Letizia Oreni; Maddalena Matone; Maria Vittoria Cossu; Nicla La Verde

Sep 11, 2026